Janney Montgomery Scott LLC boosted its stake in shares of SPDR S&P Biotech (NYSEARCA:XBI) by 10.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 98,057 shares of the exchange traded fund’s stock after buying an additional 9,655 shares during the period. Janney Montgomery Scott LLC’s holdings in SPDR S&P Biotech were worth $7,568,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of XBI. Russell Investments Group Ltd. boosted its stake in shares of SPDR S&P Biotech by 61.7% in the second quarter. Russell Investments Group Ltd. now owns 49,141 shares of the exchange traded fund’s stock worth $3,792,000 after buying an additional 18,746 shares during the last quarter. Bray Capital Advisors boosted its stake in shares of SPDR S&P Biotech by 120.3% in the second quarter. Bray Capital Advisors now owns 15,610 shares of the exchange traded fund’s stock worth $1,205,000 after buying an additional 8,525 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its stake in shares of SPDR S&P Biotech by 4.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 8,692 shares of the exchange traded fund’s stock worth $671,000 after buying an additional 346 shares during the last quarter. Meridian Wealth Management LLC acquired a new stake in shares of SPDR S&P Biotech during the second quarter worth about $432,000. Finally, FineMark National Bank & Trust boosted its stake in shares of SPDR S&P Biotech by 7.4% in the second quarter. FineMark National Bank & Trust now owns 5,210 shares of the exchange traded fund’s stock worth $402,000 after buying an additional 360 shares during the last quarter.

Shares of SPDR S&P Biotech (NYSEARCA:XBI) traded up 1.75% during midday trading on Friday, reaching $75.77. 5,417,227 shares of the company’s stock were exchanged. SPDR S&P Biotech has a one year low of $53.15 and a one year high of $82.38. The firm has a 50 day moving average of $78.49 and a 200-day moving average of $71.56. SPDR S&P Biotech also was the target of unusually large options trading activity on Thursday. Stock investors acquired 35,792 put options on the stock. This represents an increase of approximately 347% compared to the typical daily volume of 8,011 put options.

WARNING: This story was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://theolympiareport.com/2017/08/12/janney-montgomery-scott-llc-boosts-stake-in-spdr-sp-biotech-xbi-updated.html.

About SPDR S&P Biotech

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with Analyst Ratings Network's FREE daily email newsletter.